T5: Emerging Virus Inactivation Technology

#UVC #Virus #Inactivation

Abstract: This relevant talk outlines a new technology employed to fight the war on COVID-19. Historically, virus inactivation, bacterial, fungal, and bacterial decontamination in hospitals was accomplished through applying a combination of heat, chemicals, and ultraviolet light. Hospital Operating rooms typically use a portable intense source of ultraviolet light at 254 nm to reduce levels not only of viruses, but common hospital pathogens such as Methicillin resistant Staphylococcus aureus, Clostridium difficile and Vancomycin resistant enterococcus. A major vector of COVID-19 infections in New York City was found to be associated with the subway system. As an Metropolitan Transport Authority consultant, Joe Jesson was invited to recommend solutions. A patented virus defense was found to be an effective solution; and is currently in pilot test throughout the subway system. It is applied inside of locked cars without any people present, between 1:00 and 4:00 am. Joe will discuss details of the test and the newest research in people-safe, upper-air Ultra Violet LED development at General Electric Labs and other approaches.

Presenter: Joseph Jesson, is currently President and Chief Technology Officer of RFSigint Group, a wireless and patent consulting company in Hamilton Square, NJ. Joe has over 35 years of experience in engineering and technology management at Motorola, CNA, Oak, and Amoco/BP in Chicago and is a co-founder of  Asset Intelligence, a General Electric corporation. He was awarded the General Electric innovation prize, the Edison Prize in 2007. Joseph is currently Adjunct ECE Professor at TCNJ.and is IEEE Princeton Life Chair. Joseph was awarded over 15 patents and holds graduate degrees from DePaul University in Chicago. Contact email: jejesson4@gmail.com

***** To attend go to www.tcf-nj.org - check out and attend other great presentations!